Paradigm Health's Study Conduct platform is now running Phase 1b and Phase 2 clinical trials for Amgen and AstraZeneca at the same time.1 The simultaneous launch, with no prior live operational history, creates concentrated liability exposure for both pharma partners.
The platform provides real-time regulatory review of clinical trial data, integrating electronic health records to support real-world evidence collection.1 At launch, four failure modes carry the highest risk: data loss, ingestion errors, EHR integration outages, and algorithmic misclassification.
Each failure mode has a distinct financial consequence. Data loss or ingestion errors corrupt the baseline dataset, potentially requiring trial restarts. EHR integration outages create gaps in patient records that undermine data completeness required for FDA submissions. Algorithmic misclassification — automated errors in patient stratification — may not surface until late-stage analysis, when corrections are most costly.
Running two high-stakes trials simultaneously splits Paradigm Health's engineering and support capacity.1 A systemic failure hits both Amgen and AstraZeneca simultaneously, compounding reputational and contractual damage.
For pharma partners, the financial stakes are high. Phase 2 trials represent investments that typically run into hundreds of millions of dollars. Invalidated trial data at this stage can mean regulatory rejection, forced re-runs, and delayed drug development timelines. Both Amgen and AstraZeneca would have grounds for liability claims if platform failures cause material trial delays or data rejection by the FDA.1
The FDA relationship introduces a second layer of risk beyond the contractual. Platforms processing clinical trial data are subject to regulatory scrutiny of their data integrity practices. Repeated failures on active trials can trigger heightened FDA review of all submissions processed through the system — a reputational problem that extends beyond any single partnership.
For investors tracking clinical-stage technology companies, Paradigm Health's launch is a binary event. A stable operational rollout with two major pharma clients validates the platform and opens the partnership pipeline. Early failures — visible to Amgen, AstraZeneca, and the FDA simultaneously — could be commercially terminal for a company whose model depends entirely on pharma trust and regulatory credibility.
The severity assessment of this operational risk is rated catastrophic with medium likelihood.1 That combination — low probability, maximum impact — is precisely the profile that creates underpriced tail risk in technology-enabled clinical partnerships.
